Stocks · News reference
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262
RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.